Company Overview and News

3
D-Day Approaches For GW Pharma

2018-06-20 seekingalpha
In fact, company's long-term prospects should be predicated on the pipeline in general and not just specifically on epidiolex.
NMUS INSY GWP

2
NMUS / Nemus Bioscience, Inc. 424B3 (Prospectus)

2018-06-13 sec.gov
nemus_424b3.htm Filed Pursuant to Rule 424(b)(3) Registration No. 333-223895 PROSPECTUS SUPPLEMENT NO. 1 (To Prospectus Dated April 17, 2018) NEMUS BIOSCIENCE, INC.
NMUS

2
NMUS / Nemus Bioscience, Inc. FORM 8-K (Current Report)

2018-06-01 sec.gov
nmus_8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION
NMUS

2
NMUS / Nemus Bioscience, Inc. null

2018-05-31 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C<@,"!O8FH-/#PO3&EN96%R:7IE9" [email protected],S$Y M.#@O3R [email protected],C
NMUS

2
NMUS / Nemus Bioscience, Inc. null

2018-05-31 sec.gov
nemus_corresp.htm Nemus Bioscience, Inc. 600 Anton Blvd., Suite 1100 Costa Mesa, CA 92626 (949) 396-0330 April 13, 2018 VIA EDGAR
NMUS

4
NMUS / Nemus Bioscience, Inc. FORM 10-Q (Quarterly Report)

2018-05-15 sec.gov
nmus_10q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION
NMUS

3
NMUS / Nemus Bioscience, Inc. FORM 8-K (Current Report)

2018-05-04 sec.gov
nmus_8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION
NMUS

2
NMUS / Nemus Bioscience, Inc. 424B3 (Prospectus)

2018-04-17 sec.gov
nemus_s1a.htm Filed pursuant to Rule 424(b)(3) Registration Nos. 333-223895 333-221733 333-216664 333-206992 333-214761 333-215645 Prospectus
NMUS

2
NMUS / Nemus Bioscience, Inc. FORM S-1 AMENDMENT NO 1

2018-04-13 sec.gov
nemus_s1a.htm As filed with the Securities and Exchange Commission on April 13, 2018 Registration No. 333-223895 NMUS

7
GW Pharma's Cannabinoid-Based Epilepsy Position Continues To Strengthen

2018-04-02 seekingalpha
Childhood Epilepsy solutions are just the first phase in a range of treatments for GW Pharma.
NMUS EMH TBQBF EMHTF INSY

3
NMUS / Nemus Bioscience, Inc. FORM S-1

2018-03-23 sec.gov
nemus_s1.htm As filed with the Securities and Exchange Commission on March 23, 2018 Registration No. 333-___________
NMUS

2
Prominent Salk Institute Neuroscientist Joins Nemus Bioscience as Scientific Consultant

2018-03-21 globenewswire
Dr. David Schubert to advise Nemus on neuroprotection and CNS applications of the company’s proprietary cannabinoid portfolio
NMUS

2
NMUS / Nemus Bioscience, Inc. FORM 10-K (Annual Report)

2018-03-19 sec.gov
nmus_10k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION
NMUS

NMUS : Nemus Bioscience Analysis and Research Report

2017-11-30 - Asif

Nemus Bioscience is a biopharmaceutical company focused on the discovery, development, and the commercialization of cannabis-based therapeutics, or cannabinoids, through its partnership with the University of Mississippi, or UM. UM has held the only contract to cultivate cannabis for research purposes on behalf of the Federal Government since 1968, and it has significant expertise in cannabis cultivation and the extraction, separation, process and manufacture of cannabis extracts. Nemus Bioscience is currently UM's sole partner for the development and commercialization of drugs derived from cannabis extracts, or cannabinoids, and the realization of this partnership will depend on the successful navigation of the complex regulatory framework for the cultivation and handling of cannabis in the United States. Recent Events and Significant Contracts UM 5050 pro-drug agreements: On September 29, 2014, the Company executed three license agreements with UM pursuant to whi...

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

CUSIP: 64046J100